Showing results (351-360 of 384) with videos related to
Sort By:
Pageof 39
Frontiers in Oncology|June 5, 2026
Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case seriesJessica S Zhang, Juliana C K Ng, Pedro Hermida de Viveiros, et al.Cancer|May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomasSeth M Pollack, Qianchuan He, Jennifer H Yearley, et al.European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.Cancer Medicine|March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literatureAnna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgeryEvan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 8, 2013
Bone cancerJ Sybil Biermann, Douglas R Adkins, Mark Agulnik, et al.JAMA Oncology|October 12, 2023
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled TrialYongwoo David Seo, Hailing Lu, Graeme Black, et al.British Journal of Cancer|March 24, 2023
Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcomaSamuel V Rasmussen, Agnieszka Wozniak, Melvin Lathara, et al.The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.Pageof 39